Diploma (LON:DPLM) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says

Diploma (LON:DPLM) had its price target boosted by stock analysts at Deutsche Bank Aktiengesellschaft from GBX 6,200 to GBX 6,400 in a research report issued on Thursday, Marketbeat.com reports. The firm presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price would suggest a potential upside of 12.03% from the stock’s current price.

Several other research analysts have also weighed in on the company. Berenberg Bank reissued a “buy” rating and issued a GBX 6,350 price objective on shares of Diploma in a research report on Wednesday, November 19th. Royal Bank Of Canada upped their target price on Diploma from GBX 6,200 to GBX 6,600 and gave the company an “outperform” rating in a research report on Thursday. Peel Hunt reaffirmed a “buy” rating and set a GBX 6,150 target price on shares of Diploma in a research note on Friday, December 19th. Shore Capital Group reiterated a “hold” rating on shares of Diploma in a report on Wednesday. Finally, Stifel Nicolaus boosted their price target on Diploma from GBX 6,200 to GBX 6,800 and gave the company a “buy” rating in a research note on Thursday. Five analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of GBX 6,023.75.

Diploma Price Performance

Shares of LON DPLM opened at GBX 5,712.95 on Thursday. The company has a market capitalization of £7.66 billion, a PE ratio of 41.61, a P/E/G ratio of 2.82 and a beta of 1.03. The company has a quick ratio of 0.80, a current ratio of 2.04 and a debt-to-equity ratio of 46.97. Diploma has a twelve month low of GBX 3,532 and a twelve month high of GBX 6,019.52. The firm has a fifty day simple moving average of GBX 5,457.51 and a 200 day simple moving average of GBX 5,425.55.

Insider Transactions at Diploma

In other news, insider Ian El-Mokadem bought 500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 14th. The stock was acquired at an average cost of GBX 5,615 per share, with a total value of £28,075. Also, insider Katie Bickerstaffe purchased 352 shares of the company’s stock in a transaction that occurred on Wednesday, January 14th. The shares were purchased at an average cost of GBX 5,645 per share, for a total transaction of £19,870.40. Insiders own 1.14% of the company’s stock.

Key Stories Impacting Diploma

Here are the key news stories impacting Diploma this week:

• Positive Sentiment: Surprise profit upgrade forced a re‑rating of consensus and sparked a ~17% share jump as investors digested stronger-than-expected guidance. Diploma shares surge 17% as surprise profit upgrade exposes the bearish consensus
• Positive Sentiment: Guidance upgrade lifted Diploma’s earnings forecasts (~15%) and prompted price-target increases (headline 6,600p), reinforcing the bullish re-rate. Diploma price target lifted to 6,600p after guidance upgrade drives 15% earnings forecast rise
• Positive Sentiment: Berenberg raised its price target sharply to GBX 7,500 and moved to a “buy” rating, signaling confidence in the upgraded outlook. Broker ratings
• Positive Sentiment: Stifel increased its target to GBX 6,800 and upgraded to “buy”, adding to the cluster of upward revisions from brokers. Broker ratings
• Positive Sentiment: Deutsche Bank raised its target to GBX 6,400 and now carries a “buy” stance, supporting the upward momentum. Broker ratings
• Positive Sentiment: Royal Bank of Canada lifted its target to GBX 6,600 and set an “outperform” rating — another well‑known house backing the upgraded story. RBC note
• Negative Sentiment: Shore Capital reaffirmed a “hold” rating on 20 March, which may have damped some of the rally and encouraged profit‑taking after the sharp run. Shore Capital Group Reaffirms Hold Rating for Diploma

About Diploma

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.